Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.

Scott R P McDonnell Van Anh NguyenNoah M WaltonCarsten MerkwirthFeng HongDeborah BergElena Tomaselli Muensterman Richard A Furie

Published in: Lupus science & medicine (2024)

Mezagitamab had a favourable safety profile in patients with moderate to severe SLE and elicited a pharmacodynamic effect consistent with CD38+ cell depletion. These findings reveal novel insights into the drug's mechanism of action and support the continued investigation of mezagitamab in autoimmune diseases.

Keyphrases

single cell
systemic lupus erythematosus
drug induced
nk cells
multiple sclerosis
early onset
genome wide
high intensity